1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly - Drugs In Development, 2022, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth and sleep apnea. Treatment includes surgery, dopamine agonists and growth hormone antagonists.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Acromegaly - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Acromegaly (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acromegaly (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 5, 7, 5, 2 and 1 respectively.
Acromegaly (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acromegaly (Hormonal Disorders).
- The pipeline guide reviews pipeline therapeutics for Acromegaly (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acromegaly (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acromegaly (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acromegaly (Hormonal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acromegaly (Hormonal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acromegaly (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- REPORT COVERAGE
- Acromegaly - Overview
- Acromegaly - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Acromegaly - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Acromegaly - Companies Involved in Therapeutics Development
- Amolyt Pharma
- Amryt Pharma Plc
- Antisense Therapeutics Ltd
- Aquestive Therapeutics Inc
- ASCIL Biopharm
- Camurus AB
- Crinetics Pharmaceuticals Inc
- Daewoong Pharmaceutical Co Ltd
- Debiopharm International SA
- DexTech Medical AB
- Enesi Pharma Ltd
- Foresee Pharmaceuticals Co Ltd
- GeneScience Pharmaceuticals Co Ltd
- Genevant Sciences Ltd
- GlyTech Inc
- Ionis Pharmaceuticals Inc
- Italfarmaco SpA
- OPKO Health Inc
- Pharmathen Global BV
- Rani Therapeutics LLC
- Strongbridge Biopharma plc
- Acromegaly - Drug Profiles
- atesidorsen sodium - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AZP-3813 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- cimderlirsen sodium - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Debio-4126 - Drug Profile
- Product Description
- Mechanism Of Action
- FP-002 - Drug Profile
- Product Description
- Mechanism Of Action
- GNV-705 - Drug Profile
- Product Description
- Mechanism Of Action
- GT-02037- - Drug Profile
- Product Description
- Mechanism Of Action
- ITF-2984 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- lanreotide acetate CR - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- lanreotide SR - Drug Profile
- Product Description
- Mechanism Of Action
- MOD-12014 - Drug Profile
- Product Description
- Mechanism Of Action
- octreotide - Drug Profile
- Product Description
- Mechanism Of Action
- octreotide - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- octreotide acetate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- octreotide acetate CR - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- octreotide acetate DR - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- octreotide acetate microspheres - Drug Profile
- Product Description
- Mechanism Of Action
- octreotide LA - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- octreotide LA - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- paltusotine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Somadex - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- veldoreotide ER - Drug Profile
- Product Description
- Mechanism Of Action
- veldoreotide IR - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Acromegaly - Dormant Projects
- Acromegaly - Discontinued Products
- Acromegaly - Product Development Milestones
- Featured News & Press Releases
- Jun 14, 2022: Amryt to present data from OPTIMAL and MPOWERED phase 3 trials open label extension of Mycapssa (oral octreotide) at ENDO 2022
- May 24, 2022: Amolyt Pharma announces abstracts accepted for presentation to the product AZP-3813 at ECE and ENDO
- May 11, 2022: Amryt announces new patent for Mycapssa
- Apr 13, 2022: Amryt Announces positive long-term safety and efficacy data for Mycapssa (oral octreotide) from the 2nd year of OPTIMAL open label extension study in acromegaly patients
- Jan 11, 2022: Amryt announces positive long-term safety and efficacy data confirming the role for mycapssa (oral octreotide) in the management of Acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide
- Jan 04, 2022: The Lancet Diabetes & Endocrinology publishes positive results for the MPOWERED phase 3 trial for Mycapssa (oral octreotide) in Acromegaly patients
- Nov 08, 2021: Crinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress
- Jun 28, 2021: Chiasma announces submission of marketing authorization application for MYCAPSSA to the European Medicines Agency
- Jun 28, 2021: Crinetics Pharmaceuticals announces dosing of first patient in phase 3 PATHFNDR-1 study evaluating oral paltusotine for the treatment of acromegaly
- May 27, 2021: Chiasma presents positive patient-reported outcomes data from its MPOWERED phase 3 trial comparing MYCAPSSA to long-acting injectables for the maintenance treatment of adults with acromegaly
- May 20, 2021: Chiasma to present encore and new data from MPOWERED phase 3 trial at upcoming e-ECE and AACE Virtual Conferences
- May 13, 2021: Acentrus specialty contracts with Chiasma to bring MYCAPSSA (octreotide) to health systems and hospitals in the Acentrus Network
- Mar 22, 2021: Chiasma presents long-term safety and efficacy data from the open-label extension study of its CHIASMA OPTIMAL phase 3 trial evaluating MYCAPSSA in patients with acromegaly at ENDO 2021
- Mar 20, 2021: Chiasma presents new positive data for MYCAPSSA from phase 3 trial MPOWERED for the maintenance treatment of acromegaly at ENDO 2021
- Mar 10, 2021: Chiasma to present new data from two phase 3 trials, CHIASMA OPTIMAL and MPOWERED, at ENDO 2021
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Acromegaly, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Acromegaly - Pipeline by Amolyt Pharma, 2022
- Acromegaly - Pipeline by Amryt Pharma Plc, 2022
- Acromegaly - Pipeline by Antisense Therapeutics Ltd, 2022
- Acromegaly - Pipeline by Aquestive Therapeutics Inc, 2022
- Acromegaly - Pipeline by ASCIL Biopharm, 2022
- Acromegaly - Pipeline by Camurus AB, 2022
- Acromegaly - Pipeline by Crinetics Pharmaceuticals Inc, 2022
- Acromegaly - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
- Acromegaly - Pipeline by Debiopharm International SA, 2022
- Acromegaly - Pipeline by DexTech Medical AB, 2022
- Acromegaly - Pipeline by Enesi Pharma Ltd, 2022
- Acromegaly - Pipeline by Foresee Pharmaceuticals Co Ltd, 2022
- Acromegaly - Pipeline by GeneScience Pharmaceuticals Co Ltd, 2022
- Acromegaly - Pipeline by Genevant Sciences Ltd, 2022
- Acromegaly - Pipeline by GlyTech Inc, 2022
- Acromegaly - Pipeline by Ionis Pharmaceuticals Inc, 2022
- Acromegaly - Pipeline by Italfarmaco SpA, 2022
- Acromegaly - Pipeline by OPKO Health Inc, 2022
- Acromegaly - Pipeline by Pharmathen Global BV, 2022
- Acromegaly - Pipeline by Rani Therapeutics LLC, 2022
- Acromegaly - Pipeline by Strongbridge Biopharma plc, 2022
- Acromegaly - Dormant Projects, 2022
- Acromegaly - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Acromegaly, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amolyt Pharma
- Amryt Pharma Plc
- Antisense Therapeutics Ltd
- Aquestive Therapeutics Inc
- ASCIL Biopharm
- Camurus AB
- Crinetics Pharmaceuticals Inc
- Daewoong Pharmaceutical Co Ltd
- Debiopharm International SA
- DexTech Medical AB
- Enesi Pharma Ltd
- Foresee Pharmaceuticals Co Ltd
- GeneScience Pharmaceuticals Co Ltd
- Genevant Sciences Ltd
- GlyTech Inc
- Ionis Pharmaceuticals Inc
- Italfarmaco SpA
- OPKO Health Inc
- Pharmathen Global BV
- Rani Therapeutics LLC
- Strongbridge Biopharma plc
